Tenax Therapeutics, Inc., has announced the quarter results for FY-2015~16.
The results shows net loss (EPS) down to -$0.50 from -$2.71 YoY.
Fiscal Year 2015 Financial Results
The Company reported a net loss of $14.1 million or $0.50 per share for the full fiscal year 2015, compared to a net loss of $25.3 million, or $2.71 per share in fiscal 2014.
The Company reported general and administrative expenses of $7.2 million for the full fiscal year 2015, compared to $13.8 million in fiscal 2014.
The Company reported research and development expenses of $6.7 million for the full fiscal year 2015, compared to $3.0 million in fiscal 2014.
As of April 30, 2015, the Company had $48.1 million in cash, including the fair value of its marketable securities, compared to $58.3 million at April 30, 2014.
View the full earnings release here.